Lung cancer /

Lung Cancer is a comprehensively revised and expanded edition the well-established, concise, multidisciplinary reference book dealing with advances in lung cancer clinical research and treatment for the clinician. Edited and authored by leading authorities in the field, it is the best concise single...

Full description

Saved in:
Other Authors: Roth, Jack A., (Editor)
Hong, Waun Ki,
(Editor)

Komaki, Ritsuko,
(Editor)
Format: Book Electronic
Language:English
Published:Hoboken, New Jersey : John Wiley & Sons, [2014]
Edition:Fourth edition.
Subjects:
Online Access:ebook Central Access is available only to authorized users.
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Lung Cancer; Contents; Contributors; Preface; CHAPTER 1 Smoking Prevention and Cessation; Overview; Introduction; Tobacco and lung cancer; Secondhand smoke andlung cancer; Smoking among lungcancer patients; Forms of tobacco; Smoked tobacco; Smokeless tobacco; Recent developments on the tobacco market; Factors explaining tobacco use; Smoking initiation; Smoking prevention; Nicotine addiction; Benefits of quitting; Smoking cessation interventions; Behavioral counseling; Pharmaceutical aids for smoking cessation; Nicotine replacement therapy; Sustained-release bupropion; Varenicline. Combination therapyUse of medications in pregnancy; Summary; References; CHAPTER 2 Lung Cancer Susceptibility and Risk Assessment Models; Introduction; Epidemiologic risk factors; Family history; Prior inflammatory diseases and disorders; Diet and nutritional risk factors; Genetic susceptibility; Candidate gene approaches; Genome-wide association studies; 6p21 and 12p13; Intermediate phenotypic assays in measuring genetic susceptibility; DNA damage and repair phenotypic assays; Cell cycle phenotypic assays; Phenotypic assays in apoptotic pathways. Emerging novel biomarkers for LC risk and early detectionLC risk assessment models; An overview of cancer risk prediction models; Concluding remarks; References; CHAPTER 3 Molecular Profiling; Introduction; Techniques used in molecular profiling; DNA sequencing; RNA profiling; Proteomics; Data analysis and statistics; Clinical applications; Early detection and diagnosis; Molecular subclassification and staging; Selection of therapy; Future directions and conclusions; Acknowledgments; References; CHAPTER 4 Somatic Genome Alterations in Human Lung Cancers; Lung cancer genetics overview. Lung adenocarcinoma genomicsMolecular alteration spectra of lung adenocarcinoma; Key genetic alterations in lung adenocarcinoma in a few selected pathways; Genetic correlates of sensitivity and resistance; Germline predisposition; Future directions; Lung squamous cell carcinoma genomics; Introduction and overview of genomic alterations of lung SqCCs; Somatic copy number alterations; Genomic features of small cell lung cancers; Previous molecular findings in SCLC; Large-scale genome analysis studies of SCLC; Biological and clinical implications of SCLC genome alterations; References. CHAPTER 5 Serum Proteomic BiomarkersNatural history of lung cancer progression and potential utility for biomarkers in the clinic; The blood proteome; Proteomic discovery platforms; Proteomic approaches for discovery and validation of blood biomarkers; MALDI-TOF MS serum analysis for diagnosis; Serum proteomics for response to therapy; Strategies to address serum proteome complexity; Liquid chromatography (LC) tandem mass spectrometry (MS/MS); Targeted proteomics using multiple reaction monitoring (LC MRM MS); Bio-analytical validation of serum protein biomarkers; Circulating autoantibodies.